Skip to content
MarketScale
‹ Back to IndustriesHealthcare

A Pulmonary Expert Weighs in on the Johnson & Johnson COVID-19 Vaccine’s Pause

The mission of Health Matters is to promote health equity by elevating the conversation around healthy habits, preventative health, and relevant public health issues. By approaching these topics with an equitable lens, we can all do our part to empower individuals to make more informed decisions about their health and care.   On this episode,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

The mission of Health Matters is to promote health equity by elevating the conversation around healthy habits, preventative health, and relevant public health issues. By approaching these topics with an equitable lens, we can all do our part to empower individuals to make more informed decisions about their health and care.

On this episode, hosts Dr. Jose Medina-Inojosa and Alisa Johnsrud talked with Jonathan Baktari, MD, about the Johnson and Johnson vaccine pause due to potentially fatal blood clots after one American died and one is in critical condition. Baktari is a pulmonary and critical care expert, vaccine expert, CEO of two medical companies —e7Health.com and US Drug Test Centers.

“It’s interesting. The mRNA vaccine has been around for ten years” -Jonathan Baktari, MD

The trio talked about the Johnson and Johnson vaccine and the importance of the other vaccines. Baktari said the vaccine would be part of the solution to get to herd immunity, so even though it’s currently delayed, it will be an essential piece of the puzzle. The Moderna and Pfizer vaccine use mRNA to introduce the virus, while the J&J vaccine uses the adenovirus.

“It’s interesting. The mRNA vaccine has been around for ten years,” Baktari said. He elaborated that nobody had the guts to use mRNA because folks would have been hesitant to inject genetic material. The pandemic, however, forced us to use the technology.

Vaccines have always been a sensitive subject, as some don’t want to use vaccines. For Baktari, he doesn’t understand the hesitancy. He noted that people are still so willing to use antibiotics and other drugs, but they don’t like it when it comes to vaccines. One of the reasons he thinks is because the government advises it.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Digital health's July 2026 signal: AI wearables, a new CMS office, and the telehealth billing fight

Digital health's July 2026 signal: AI wearables, a new CMS office, and the telehealth billing fight

In mid-2026, digital health is evolving with significant advancements such as AI-driven wearables and innovations in healthcare billing processes involving telehealth. A notable cardiac patch boasting 99.6% accuracy highlights progress in wearable technology. Meanwhile, the establishment of a new CMS AI office demonstrates the growing institutional interest in integrating AI into healthcare operations.

  • 01AI wearables are being developed with high accuracy in health monitoring.
  • 02The establishment of a CMS AI office indicates increased government focus on AI in healthcare.
  • 03Debates over telehealth billing practices continue to shape the healthcare landscape.

Jul 5, 2026

OpenLoop acquires AI communication platform Hey Revia as digital health M&A heats up

OpenLoop acquires AI communication platform Hey Revia as digital health M&A heats up

OpenLoop has acquired AI communication platform Hey Revia as part of growing M&A activity in the digital health sector. The acquisition reflects an ongoing trend in digital health mergers and partnerships, including the announcement of FDA breakthrough status for Aurenar and Sharecare's collaboration with AWS. These developments highlight the increasing investment and strategic alliances shaping the digital health landscape.

  • 01OpenLoop acquires AI communication platform Hey Revia.
  • 02FDA grants Aurenar breakthrough status.
  • 03Sharecare partners with AWS to enhance digital health solutions.

Jul 4, 2026

Healthcare AI governance, data quality, and interoperability top industry agenda in mid-2026

Healthcare AI governance, data quality, and interoperability top industry agenda in mid-2026

The article discusses the challenges faced by healthcare IT leaders in terms of AI governance, data quality, and interoperability by mid-2026. A significant effort is being made to address data readiness challenges and to enhance health data exchange through a $1.3 million federal initiative. These topics are at the forefront of the industry's agenda to improve healthcare infrastructure and outcomes.

  • 01AI governance gaps are challenging healthcare IT leaders.
  • 02Data readiness is a critical concern in healthcare.
  • 03Federal funding is supporting health data exchange initiatives.

Jul 2, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub